# RabPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rabpharma

- Industry: Biotechnology
- Headquarters: Zhongshan, China
- Website: www.rabpharma.com
- Latest round: Series A (Aug 31, 2023)
- Investors on record: 4

## About

Based in Zhongshan, China, and founded in 2021, RabPharma is a biopharmaceutical company focusing on the research and development of peptide-drug conjugate (PDC). It has reached a collaboration agreement with Regenerative Arthritis & Bone Medicine, Inc. to acquire the rights to develop and commercialize a series of innovative drugs (RABs). It also has partnerships with In October 2022, RAB001 received drug clinical trial approval from the Drug Review Center of the State Drug Administration of China. The company's Chief Scientist Officer, Wei Yao, is a professor at the University of California, Davis, and she has been involved in drug discovery and development for Pfizer, Amgen, GlaxoSmithKline, etc. In September 2025, RabPharma closed a series A++ led by returning investor Baheal Pharmaceutical Group with participation from new investors Cheng Du Sheng Nuo Biotec Co.,Ltd, Chenghai Venture Capital, Oriental Morning Star and returning investor Zhuhai Yihao Investment.
The company focuses on RAB-002, RAB-003, and RAB-004 as well as YLLs, bone regeneration drugs such as herbal compounds containing hyssop, small molecule drugs for the treatment of osteoarthritis, PR-Inhs and bone-targeted super-nano-carrying drugs, nanoporphyrin analogs, and other new products and the application of new technologies. It has built a technology platform for PDC coupling and high-throughput screening, etc. The product for osteonecrosis treatment, RAB001, has already completed the Phase I clinical trial in the U.S. and has been granted the CDE clinical approval in China. 
It generates revenue through research development and industrialization of new innovative bone and joint drugs.
The series A++ round of funds will focus on advancing the pipeline RAB001d and RAB202 projects, while consolidating the company's technology platform and team building.

## Funding rounds

- Series A, Aug 31, 2023 — Hecheng Capital, Baheal Medical, Zhongshan Venture Capital, Zhuhai Yihao Investment

## Investors

- Hecheng Capital (https://capitalatlas.ai/funds/hecheng-capital) — Series A
- Baheal Medical — Series A
- Zhongshan Venture Capital (https://capitalatlas.ai/funds/zhongshan-venture-capital) — Series A
- Zhuhai Yihao Investment — Series A